Titan Medical Inc. Registration statement for securities of certain foreign private issuers

Registration statement for securities of certain foreign private issuers

Statement of Shareholders' Equity and Deficit

Statement of Shareholders' Equity and Deficit - USD ($)	Issued capital [member]	Share premium [member]	Share Warrants [member]	Retained earnings [member]	Total
Beginning balance at Dec. 31, 2017	$ 154,016,519	$ 5,146,784	$ 741,917	$ (150,298,422)	$ 9,606,798
Beginning balance, share at Dec. 31, 2017	12,686,723
Statement Line Items [Line Items]
Issued pursuant to agency or common share purchase agreement	$ 16,915,394				16,915,394
Issued pursuant to agency or common share purchase agreement, shares	8,975,126
Share issue expense	$ (1,297,668)				(1,297,668)
Issued other	$ 66,234				66,234
Issued other, shares	7,500
Warrants exercised during the year	$ 59,998				59,998
Warrants exercised during the year, shares	6,500
Warrants expired during the year	$ 741,917		$ (741,917)
Stock based compensation		1,505,625			1,505,625
Net and Comprehensive loss				(22,639,272)	(22,639,272)
Ending balance at Dec. 31, 2018	$ 170,502,394	6,652,409		(172,937,694)	$ 4,217,109
Ending balance, shares at Dec. 31, 2018	21,675,849				21,675,849
Statement Line Items [Line Items]
Issued pursuant to agency or common share purchase agreement	$ 13,717,131				$ 13,717,131
Issued pursuant to agency or common share purchase agreement, shares	8,455,882
Share issue expense	$ (1,495,501)				(1,495,501)
Warrants exercised during the year	$ 7,002,043				7,002,043
Warrants exercised during the year, shares	1,018,506
Stock based compensation		251,357			251,357
Net and Comprehensive loss				(28,282,880)	(28,282,880)
Ending balance at Mar. 31, 2019	$ 189,726,067	6,903,766		(201,220,574)	(4,590,741)
Ending balance, shares at Mar. 31, 2019	31,150,237
Beginning balance at Dec. 31, 2018	$ 170,502,394	6,652,409		(172,937,694)	$ 4,217,109
Beginning balance, share at Dec. 31, 2018	21,675,849				21,675,849
Statement Line Items [Line Items]
Issued pursuant to agency or common share purchase agreement	$ 13,717,131				$ 13,717,131
Issued pursuant to agency or common share purchase agreement, shares	8,455,882
Issued private placement	$ 5,727,971				5,727,971
Issued private placement, shares	8,757,444
Share issue expense	$ (2,090,124)				(2,090,124)
Warrants exercised during the year	$ 7,002,043				7,002,043
Warrants exercised during the year, shares	1,018,506
Stock based compensation		1,651,118			1,651,118
Net and Comprehensive loss				(41,907,079)	(41,907,079)
Ending balance at Dec. 31, 2019	$ 194,859,415	8,303,527		(214,844,773)	$ (11,681,831)
Ending balance, shares at Dec. 31, 2019	39,907,681				39,907,681
Statement Line Items [Line Items]
Issued pursuant to agency or common share purchase agreement	$ 3,037,204				$ 3,037,204
Issued pursuant to agency or common share purchase agreement, shares	11,909,196
Share issue expense	$ (214,263)				(214,263)
Warrants exercised during the year	$ 1,011,120				1,011,120
Warrants exercised during the year, shares	2,400,000
Stock based compensation		228,576			228,576
Net and Comprehensive loss				(768,043)	(768,043)
Ending balance at Mar. 31, 2020	$ 198,693,476	$ 8,532,103		$ (215,612,816)	$ (8,387,237)
Ending balance, shares at Mar. 31, 2020	54,216,877				54,216,877